Objective: The aim of this study was to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines.
S
ince their first description 1 and histological classification, 2 intraductal papillary mucinous neoplasms (IPMNs) of the pancreas have been diagnosed more frequently and with progressively smaller incidental lesions in the recent years. 3 Because of their malignant potential, surgical resection was initially recommended for all IPMN lesions independently of their features. However, after the Sendai 4 and updated Fukuoka 5 guidelines, this surgical approach was substituted by a more conservative surveillance strategy. This trend was also reflected in the recently published American Gastroenterological Association (AGA) guidelines, 6 which suggest discontinuation of surveillance after 5 years in low-risk lesions if cyst features are unchanged.
Despite these advances, currently published guidelines lack sufficient evidence to be considered more than expert recommendations or consensus guidelines. The main problem lies in the absence of long-term follow-up IPMN studies to describe the natural history of these lesions. Therefore, the current recommendations should be considered carefully, and the management strategy should be tailored for each patient.
As a result, the aim of this study was to analyze the long-term outcomes of a large longitudinal IPMN-focused international cohort. The secondary aim was to evaluate the new AGA pancreatic cystic neoplasm guidelines based on our study cohort.
MATERIALS AND METHODS
The study was approved by the Mayo Clinic Institutional Review Board and the Human Safety Committee of every participating center. This is a retrospective longitudinal study using a prospectively maintained IPMN registry. This registry involves a total of 6 centers: 5 Every patient with a clinical suspicion of IPMN following the current guidelines criteria 5 who also had a high-resolution imaging study performed as a baseline examination was included in the database, based on comprehensive reviews of the electronic health records at each institution. Following the 2012 Sendai guidelines, 5 a high suspicion of IPMN was defined as the presence of a segmental or diffuse main pancreatic duct (MD) dilation (>5 mm) or the visualization of a cyst communicating with the MD and without other causes of obstruction. The study information was obtained from the clinical databases of each participant center. In the case of MCJ, those patients who were not actively followed in this institution were contacted by mail and phone call to obtain further information. An initial demographic form was filled once per patient, followed by a visit form containing the clinical, imaging, and surgical features, if present. This last form was completed for each follow-up visit. For the imaging variables, the measurements and features of the cysts were extracted from the imaging study performed in that visit. If more than one study was done within the same visit, a predetermined order of inclusion was applied: first endoscopic ultrasound, then magnetic resonance imaging, and finally computed tomography scan. If more than one cyst was described, the characteristics of the largest one were entered.
From the total number of patients included in the registry, the following exclusion criteria were applied to obtain the final study cohort. Patients with a high but nonconfirmed suspicion of malignancy that could not undergo surgical resection because of their comorbidities or stage of the tumor were excluded because of the absence of pathological confirmation. Only the patients with more than 1-year follow-up were included in the analysis. From the remaining sample, patients were also excluded if the diagnosis of malignancy occurred within the first 3 months since the initial visit (prevalent cases). Malignancy was defined as the presence of pathologically confirmed high-grade dysplasia (HGD) IPMN or IPMN-derived invasive carcinoma.
A secondary subgroup was created following the new AGA guideline criteria. Only those patients who had in their initial visit a less than 3-cm branch duct (BD) IPMN, without solid intracystic component and no MD dilation, were identified. Second, those patients with follow-up longer than 5 years were identified, and their clinical and imaging characteristics from the initial and the lost-to-follow-up (LFU) visit were compared.
Statistical Analysis
The REDCap database (Research Electronic Data Capture, Nashville, Tenn; hosted by Mayo Clinic) was used to build the registry and manage the data. The statistical analysis was performed using the Stata 13 software for Mac OS X Lion (Stata Inc, College Station, Tex).
Values were expressed as percentages, medians, or ranges, as indicated. Continuous variables were analyzed with a two-tailed Student's t-test, and categorical variables were compared using a χ 2 test or Fischer's exact test when appropriate. For the survival analysis, the event under study was the diagnosis of malignancy. Patients who were actively followed without a malignant diagnosis at their last follow-up visit were considered censored times. Any patient was considered "lost" if no follow-up was performed within 3 years 5 of the last visit and no death notification was obtained from their clinical charts or direct communication with their familiars. Because of the large sample size, the survival analysis was conducted following the actuarial/life-table method, grouping the participation time in intervals of 6 months each. In addition, the conditional mortality rate was calculated with a hazard function. A regression model for recurrent events was not applied in this analysis because of the low number of recurrences seen in our sample, as it would have prevented robust coefficient estimation. Therefore, in those cases where 2 diagnoses of malignancy were done, the first diagnosis was the one considered for the survival analysis.
RESULTS
Overall, 1180 patients were entered in the registry. Of these, a total of 620 patients met all the inclusion criteria and, therefore, were included in the study: 472 from MCJ, 79 from Azienda Universitario-Ospedaliera San Giovanni Battista, 53 from San Raffaele Scientific Institute, 12 from Humanitas Research Hospital, and 4 from University of Bologna/Hospital of Imola. The first patient was visited in July 1999 and the last one in May 2014. Follow-up visits were updated until June 2015.
There was a predominance of female sex (63%) and white race (93%), with an overall median age at diagnosis of 67.5 years and a median body mass index of 25.9. The smoking history was almost equally distributed (54% nonsmokers vs 46% current/ previous smokers). Forty-two patients (7%) had a positive family history of pancreatic cancer.
Only 37% of the cohort was symptomatic at the initial visit. Abdominal pain was the most frequent symptom followed by weight loss. Endoscopic ultrasound was the dominant imaging method (recorded in 84% of the initial visits) followed by magnetic resonance imaging (10%). Most (89%) of the lesions were BD-IPMNs, with a median of 1 cyst diagnosed per patient. Clinical and imaging features are summarized in Table 1 .
The study population was followed-up for a median of 3 years, with a maximum period of 13 years. During this time, 37 (6%) patients developed malignancy, 52 (9%) died due to nonpancreatic causes, 393 (63%) had censored times, and 138 (22%) were LFU. All malignant cases were diagnosed within the first 6 years, except for 1 isolated case that was diagnosed during the 11th year of follow-up. This case was a 62-year-old woman at study entry with an IPMN diagnosed after a unique episode of acute pancreatitis. Surveillance was performed from 2001 to 2014, with a total of 12 follow-up visits. During that time, the only worrisome feature was a less than 10 mm-dilated MD that was not constantly described. The only referred symptom (steatorrhea) was reported in the same visit when the malignancy was suspected. The pathological report described an IPMN-derived invasive ductal adenocarcinoma.
The median study cohort time from the initial visit to the malignant diagnosis was 10.3 months (range, 4-134 months). No significant differences were seen in the time until malignant diagnosis between the BD-IPMNs and the group involving both MD/mixed IPMNs (P = 0.27). The 1-, 5-, and 10-year actuarial rates of survival were 97%, 93%, and 92%, respectively (Fig. 1) . During the first year, the incidence of malignancy was 34.5 cases per 1000 persons/year (95% confidence interval [CI], 22.5-52.9). A second peak was observed in the sixth year of follow-up, with an incidence of 15.3 cases per 1000 persons/year (95% CI, 3.8-61.1) (Fig. 2) . Overall, 5 patients underwent 2 different surgical resections during their surveillance; the initial benign diagnosis turned malignant in only 1 case (Supplemental Table 1 , http://links.lww.com/ MPA/A549).
A total of 431 patients had low-risk lesions (<3-cm BD-IPMN, with no solid intracystic component or pancreatic duct dilation) described in the initial visit. The median follow-up time was also 3 years. Eight (2%) malignancies were diagnosed in this subgroup, all of them within the first 5 years (Table 2 ). In all but 2 cases, a newly seen worrisome feature was reported in a follow-up imaging study, which ultimately led to the surgical decision. The 1-, 5-, and 10-year actuarial rates of survival were 99%, 97%, and 97%, respectively (Fig. 3) . The incidence of malignancy was 4.9 cases per 1000 persons/year (95% CI, 2.5-9.8), which lowered to 3.7 cases per 1000 person/year (95% CI, 1.7-8.2) if the malignant cases diagnosed within the first year of follow-up were excluded.
From this subgroup, 112 patients had a follow-up time greater than 5 years. In this cohort, no malignancy was found during the entire surveillance. The results showed 96 (86%) censored patients, 10 (9%) nonpancreatic deaths, and 6 (5%) LFU patients, with a median follow-up of 7 years (range, 60-141 months). The main changes that occurred during the surveillance time are summarized in Supplemental Table 2 , http://links.lww.com/ MPA/A550.
DISCUSSION
In this study, we show the minimal risk of malignant development after the first 5 years of follow-up if no worrisome features were seen in this initial 5-year period.
One of the primary concerns regarding IPMNs is their uncertain natural history. Most of the initial studies were based on surgical cohorts [7] [8] [9] that led to an overestimation of the malignancy rates due to the inherent selection bias. However, with the more recent publication of observational studies, 10 ,11 the estimated risk is significantly lower, 12 and conservative management strategies have been increasingly recommended for low-risk IPMNs.
As a consequence of the exclusion criteria herein applied, this study cohort involved mostly low-risk IPMNs. Most of the lesions (89%) were BD-IPMNs with no mural nodules (92%) and no septae (72%) and with a small size (median, 1.5 cm). These 4 variables are well-established predictors of indolent course in IPMNs. 13, 14 Most of the patients included in the study were asymptomatic in the initial visit. When symptoms were analyzed separately, abdominal pain was the most common. This last finding is a very nonspecific sign that patients frequently present with in daily practice. In a study performed by our group, 15 abdominal pain alone was not associated with malignant IPMN in contrast to more pancreas-specific symptoms such as steatorrhea or jaundice. These latter symptoms rarely presented in our current study cohort.
A total of 37 (6%) patients had a pathologically confirmed malignant diagnosis. This proportion fits with current literature findings ranging from 2% to 6%. [16] [17] [18] [19] However, all these studies were exclusively BD-IPMN focused. Taking into consideration the characteristics of our study cohort, it is not surprising that the results regarding the overall proportion of malignancy were very similar. Despite this, there was a noticeable difference between the median times until the malignant diagnosis. Except for 1 patient, malignancy was diagnosed within the first 6 years of surveillance, with a median time of 10 months. In the study by Sawai et al, 16 the median follow-up time before the diagnosis was 93 months, whereas in the study by Malleo et al, 19 it was 29 months. We performed a subanalysis to specifically evaluate whether the presence of MD and mixed IPMNs in our cohort (12% of the cases) was responsible for these earlier diagnosis times, but no significant differences were seen among groups (P = 0.27).
The actuarial survival analysis confirmed the low malignancy risk of a cohort involving IPMNs without any worrisome feature. The 5-and 10-year actuarial rates of developing any pancreatic malignancy were 7% and 8%, respectively, which are slightly higher than the previously reported results by Malleo et al 19 (1.4% and 4.6%, respectively). As expected, the conditional malignancy rate showed the highest value during the first year, with a secondary peak during the sixth year of follow-up. After this period of time, no other malignancy was diagnosed, except for an isolated case during the 11th surveillance year. However, the presence of a dilated MD would have excluded this patient from a long-term surveillance program. The AGA recently published new guidelines for the management of pancreatic cystic neoplasms. 6 Special attention should be given to one of the recommendations against continued surveillance if there is no significant change (ie, development of a solid component, increasing size of the pancreatic duct, and/or diameter ≥3 cm) in the cyst features after 5 years of follow-up. This is the first time that a guideline has addressed the problematic issue of when to stop surveillance of low-risk lesions. Until now, the absence of good-quality evidence for this recommendation limits generalizability.
In our subgroup of patients with the above-mentioned characteristics, a total of 8 malignancies were diagnosed, all within the first 5 years of follow-up. Moreover, 6 of these cases developed at least 1 of the worrisome features that must not be present if the surveillance program is to be discontinued. If only those patients with surveillance times greater than 5 years were considered, no malignant cases were seen.
In accordance to our findings, the new recommendations exposed in the AGA guidelines seem safe. The described cyst parameters would detect any sign of incipient malignancy, and the suggested timeline would be enough to diagnose the malignant cases. However, there are some discrepancies in the current literature. Some studies involving BD-IPMNs have reported cases of malignancy (whether BD-IPMN-derived 18 or synchronous carcinoma 20 ) that developed after the initial 5 years. Hence, they concluded that follow-up should not be discontinued in any surgical candidate due to the latent risk of malignancy.
Presently, the current IPMN management strategy tends toward a more conservative approach. As it has happened with other precursor lesions, such as Barrett disease, newer studies have exposed an overestimation of the initially reported malignant transformation incidence rates. In Barrett disease, the malignant development follows also a progressive pattern from low-grade dysplasia to HGD and finally adenocarcinoma. Recent studies 21 have reported rather low incidence rates for HGD or adenocarcinoma development in low-risk Barrett lesions. Hvid-Jensen et al 22 reported a value of 5.1 cases per 1000 person/year if the malignant cases diagnosed within the first year of follow-up were excluded. This is remarkably similar to our 4.9 cases per 1000 person/year. Thus, one could consider low-risk IPMN to be quite similar to low-risk Barrett esophagus. Current Barrett esophagus guidelines do advocate for ongoing surveillance in low-risk Barrett esophagus patients. Whether the same principal should be applied to IPMN is a matter of debate; however, our data suggest that the 2 conditions should be considered to have similar risk.
Last, we compared the cyst characteristics between the initial and the LFU visit in the low-risk long-term cohort. The results did not show any statistically significant difference between the number, size, duct, or cyst location. Moreover, improvement was seen regarding the septae description and the presence of symptoms, specifically abdominal pain. Mural nodules, which are strongly suggestive of malignancy, 23, 24 were never described during the entire surveillance. These results also support the new guideline's recommendation by demonstrating not only the absence of malignant development but also the stability of the main cyst's features after the initial years of surveillance. This trend toward stability in the cyst after the initial follow-up period has also been described in previous studies 17, 25, 26 that focused on BD-IPMNs without mural nodules during mid-and long-term follow-ups (median, 3-5 years). There are some limitations in this study. First of all, the global median follow-up time was 3 years, limiting the description of the long-term IPMN behavior. To minimize this, we separately analyzed a subcohort, including only those patients whose surveillance times were greater than 5 years. On the other hand, as it is a retrospective study involving a broad time range (from 1999 to the present year), some of the patients were LFU. To solve this limitation, we directly contacted each of these patients to invite them to provide more information, managing to reduce the LFU percentage to 22%.
This study directly addresses the new AGA guideline recommendations regarding surveillance of IPMN-focused cohorts. The results herein support the new trend toward more conservative IPMN management. However, the presence of previous studies showing contradictory results highlights the necessity of more long-term IPMN data.
